348 related articles for article (PubMed ID: 28678782)
1. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma.
Miller TE; Liau BB; Wallace LC; Morton AR; Xie Q; Dixit D; Factor DC; Kim LJY; Morrow JJ; Wu Q; Mack SC; Hubert CG; Gillespie SM; Flavahan WA; Hoffmann T; Thummalapalli R; Hemann MT; Paddison PJ; Horbinski CM; Zuber J; Scacheri PC; Bernstein BE; Tesar PJ; Rich JN
Nature; 2017 Jul; 547(7663):355-359. PubMed ID: 28678782
[TBL] [Abstract][Full Text] [Related]
2. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.
Yu D; Khan OF; Suvà ML; Dong B; Panek WK; Xiao T; Wu M; Han Y; Ahmed AU; Balyasnikova IV; Zhang HF; Sun C; Langer R; Anderson DG; Lesniak MS
Proc Natl Acad Sci U S A; 2017 Jul; 114(30):E6147-E6156. PubMed ID: 28696296
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation.
Mallm JP; Windisch P; Biran A; Gal Z; Schumacher S; Glass R; Herold-Mende C; Meshorer E; Barbus M; Rippe K
Int J Cancer; 2020 Mar; 146(5):1281-1292. PubMed ID: 31456217
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases.
Dixit D; Prager BC; Gimple RC; Miller TE; Wu Q; Yomtoubian S; Kidwell RL; Lv D; Zhao L; Qiu Z; Zhang G; Lee D; Park DE; Wechsler-Reya RJ; Wang X; Bao S; Rich JN
Sci Transl Med; 2022 Jan; 14(626):eabf3917. PubMed ID: 34985972
[TBL] [Abstract][Full Text] [Related]
6. Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma.
Mack SC; Singh I; Wang X; Hirsch R; Wu Q; Villagomez R; Bernatchez JA; Zhu Z; Gimple RC; Kim LJY; Morton A; Lai S; Qiu Z; Prager BC; Bertrand KC; Mah C; Zhou W; Lee C; Barnett GH; Vogelbaum MA; Sloan AE; Chavez L; Bao S; Scacheri PC; Siqueira-Neto JL; Lin CY; Rich JN
J Exp Med; 2019 May; 216(5):1071-1090. PubMed ID: 30948495
[TBL] [Abstract][Full Text] [Related]
7. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
9. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.
Bhaskaran V; Nowicki MO; Idriss M; Jimenez MA; Lugli G; Hayes JL; Mahmoud AB; Zane RE; Passaro C; Ligon KL; Haas-Kogan D; Bronisz A; Godlewski J; Lawler SE; Chiocca EA; Peruzzi P
Nat Commun; 2019 Jan; 10(1):442. PubMed ID: 30683859
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
11. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.
Singer E; Judkins J; Salomonis N; Matlaf L; Soteropoulos P; McAllister S; Soroceanu L
Cell Death Dis; 2015 Jan; 6(1):e1601. PubMed ID: 25590811
[TBL] [Abstract][Full Text] [Related]
12. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
13. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
15. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
[TBL] [Abstract][Full Text] [Related]
16. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
[TBL] [Abstract][Full Text] [Related]
17. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
18. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
Shen J; Chen M; Lee D; Law CT; Wei L; Tsang FH; Chin DW; Cheng CL; Lee JM; Ng IO; Wong CC; Wong CM
Gut; 2020 Feb; 69(2):329-342. PubMed ID: 31439637
[TBL] [Abstract][Full Text] [Related]
19. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.
Sa JK; Kim SH; Lee JK; Cho HJ; Shin YJ; Shin H; Koo H; Kim D; Lee M; Kang W; Hong SH; Kim JY; Park YW; Song SW; Lee SJ; Joo KM; Nam DH
Neuro Oncol; 2019 Feb; 21(2):222-233. PubMed ID: 29939324
[TBL] [Abstract][Full Text] [Related]
20. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
